Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
How to Evaluate Compounded Tirzepatide Vendors: A 2026 Framework
articleA methodology-first guide to evaluating compounded tirzepatide vendors. Learn the 503A vs 503B distinction, why a prescription is non-negotiable, how to read a Certificate of Analysis, and the five signals that separate legitimate sources.
Vendor Safety Methodology: How GLP3Planner Evaluates Peptide Sourcing
referenceEditorial methodology for vendor evaluation: 40 active US peptide research-chemical vendors assessed across six criteria, third-party verified against Finnrick Analytics and Janoshik Analytical, with the market reshuffle context that changed the trust calculus in 2025-2026.